FDA approves Roche and Daiichi's skin cancer drug Zelboraf

08/17/2011 | Bloomberg

The FDA granted marketing approval for Roche Holding and Daiichi Sankyo's Zelboraf to treat melanoma patients whose disease has spread and cannot be treated by surgery. The drug, also called vemurafenib, disrupts a gene mutation contributing to tumor growth. It is the second melanoma treatment approved this year that "demonstrates an improvement in overall survival," said FDA official Richard Pazdur.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA